Optimizing PARPi in Ovarian Cancer: Practical Guidance on Current Clinical Management Strategies

Review the latest data and expert guidance on PARP inhibitors to enhance your treatment of ovarian cancer. This comprehensive program features decision support tools focused commentaries an expert analysis module and a downloadable slideset.

Share

Program Content

Activities

PARPi in Ovarian Cancer
How I Am Using PARP Inhibitors in the Care of Patients With Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 02, 2019

Expires: April 30, 2020

ASCO 2019 Data on PARPi
PARP Inhibitors in Recurrent Ovarian Cancer: What’s New at ASCO 2019
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2019

Expires: June 22, 2020

PARPi Dosing and Safety
Dosing and Safety of PARP Inhibitors in Ovarian Cancer: Tips From My Clinic
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 27, 2019

Expires: August 25, 2020

QUADRA Trial Implications
My Thoughts on the Clinical Implications of the Expanded Indication for Niraparib
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 26, 2019

Expires: November 24, 2020

Activities

PARPi in Ovarian Cancer
Multidisciplinary Expert Insights and Guidance on Using PARP Inhibitors in Ovarian Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 25, 2019

Expires: September 23, 2020

Provided by

ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro